- Updated Survival and Biomarker Data for Ipilimumab to be Presented -
PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that the following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an anti-PD-1 antibody for cancer treatment, have been selected to be the subject of presentations at the Annual Meeting of the American Society of Clinical Oncology, being held May 29-June 2, 2009 in Orlando:
Survival, Response, Safety and Biomarker Data of Ipilimumab in Melanoma
Response and Safety Data of Ipilimumab in Prostate
Clinical Data of MDX-1106 in Cancer
More information about the ASCO Annual Meeting may be found at www.asco.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved for commercial sale. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216; Nichol
Ochsner, Corporate Communications (media), +1-609-430-2880, x2214
Web site: http://www.medarex.com/
